GLP-1 function and effectiveness and discuss how to ensure patient access, affordability, and safety.
Obesity is still considered as social stigma and taking medicines for obesity is considered as “easy way out”. Experts emphasize that this type of perceptions create major hurdles for patients trying to access treatment for obesity
Obesity is a chronic and relapsing disease requiring lifelong management:
Similar to the condition of high blood pressure or high cholesterol obesity is a chronic disease and relapses after discontinuation of the medicines. GLP-1 addresses obesity while active in the body. That is why patients who have discontinued the use of GLP-1 medication tend to resume after an year. The GLP-1 has Rebound Effect. This “rebound effect” illustrates that GLP-1s manage the chronic disease effectively, but function as only one component of a multidisciplinary care approach
High Treatment Discontinuation Rates: The study shows that the GLP-1 medications who began their journey on lifelong care stopped taking medicine within one year and half of those later resumed the medication.
Need for Comprehensive Care: One needs to understand that the obesity is a complex disease and the solution medical care along with lifelong persistent activities are even more complex to address this issue one need good understanding of the subject and proper care for the treatment.
GLP-1 Agonists are Safe
According to medical experts at the National Academy of Medicine event the following considerations are important to understand the safety of GLP-1 agonists.
Established Long-Term Track Record: GLP-1 medicines are proven safe and effective the conclusion is supported by two decades of clinical use of these medicines in treating diabetes. Other than weight loss and blood sugar control it is proven effective for reducing the risk of heart attacks and strokes.
Risks of Muscle Loss and Malnutrition: its side effects can alter eating habits which can be risky if it is not monitored properly. Older people especially with history of cardiovascular disease—require clinical support to ensure adequate nutrition and physical activity to prevent reductions in muscle mass and physical function.
Caution Regarding Compounded Alternatives: Since GLP-1 are expensive people usually go for compounded alternatives at the retailers. Panelists say because these alternatives are formulated differently from brand name drugs. It becomes difficult for doctors to determine its effectiveness or safety.
Importance of Doctor-Supervised Wraparound Care:
GLP-1 medications prescribed by Physicians are generally safe. But Experts stress that it should mandatorily be integrated with nutritional counseling, physical activity support, and lifestyle monitoring. This will help with risks like malnutrition and fall risks associated with muscle loss.
How do compounding pharmacies impact GLP-1 safety?
Compounding pharmacies and online retailers produce alternative GLP-1 formulations primarily in response to the high cost and scarcity of brand-name medications
According to the panelists, compounding pharmacies impact GLP-1 safety in the following ways:
Different Regulatory Oversight:
Compounding pharmacy retailers offer medicines that has not been approved by FDA. It is recommended to use FDA approved brand names GLP-1 agonists
Inconsistent Quality & Dosing:
There are inconsistencies on how these alternative formulations are composed assembles labelled and dosed
Impaired Clinical Oversight:
Due to variation in labelling and dose the doctors find it difficult to manage correct dose of the medicines, making it challenging to monitor risks or predict how the drug will affect them.
GLP-1s Are Expensive, But Changes Are expected
GLP-1 drugs are highly expensive- but different market and policies and formulation shifts are working on the price change.
Current Cost Barriers: GLP-1 medications often cost more than $1,000 per month. While insurance coverage and discount programs can reduce these costs. The medications remain financially out of reach for many patients
Expanding Medicare & Federal Coverage: Federal programs like TRICARE and Medicaid cover certain obesity treatments, and Medicare is working to overcome a regulatory barrier to cover GLP-1s. Expanding insurance will broaden the access to many patients.
Development of Oral Pill Formulations: most of the GLP-1 medicines are administered through injections. Oral pill based formulations are expected to raise the market significantly.
Balancing Innovation & Affordability: Policy experts are emphasizing on the need for insurer and subsidies to expand meanwhile preserving incentives for developers for need of innovations.
Potential Over-the-Counter Proposals: Some policy experts have proposed the need for making GLP-1 availble without prescription to lower costs and expand access. This is highly unlikely acceptable proposition by the healthcare professionals as it can lead to much harm to the patients
GLP-1 medicines are safe to use its two decades use on type 2 diabetes patients have shown proven results. It is being strategize to make it accessible to all the needy patients however its high cost makes it challenging to reach everyone in need. Obesity is a chronic relapsing disease that require lifelong management.